https://orcid.org/0000-0002-8397-6863
References
- Ysebaert L, Fournié J-J. Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52(7):1404–1406.
- Tsukada N, Burger JA, Zvaifler NJ, et al. Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002;99(3):1030–1037.
- Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655–2663.
- Galletti G, Scielzo C, Barbaglio F, et al. Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression. Cell Rep. 2016;14(7):1748–1760.
- Hanna BS, McClanahan F, Yazdanparast H, et al. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia. 2016 ;30(3):570–579.
- Uribe-Querol E, Rosales C. Control of phagocytosis by microbial pathogens. Front Immunol. 2017;8:1368.
- Burgess M, Mapp S, Mazzieri R, et al. Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients. Oncogene. 2017 ;36(17):2366–2376.
- Goede V, Hallek M. Pharmacotherapeutic management of chronic lymphocytic leukaemia in patients with comorbidities: new agents, new hope. Drugs Aging. 2015;32(11):877–886.
- Church AK, VanDerMeid KR, Baig NA, et al. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. Clin Exp Immunol. 2016;183(1):90–101.
- Lefebvre ML, Krause SW, Salcedo M, et al. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother. 2006;29(4):388–397.
- Boissard F, Fournie JJ, Laurent C, et al. Nurse like cells: chronic lymphocytic leukemia associated macrophages. Leuk Lymphoma. 2015;56(5):1570–1572.
- Hallek M, International Workshop on Chronic Lymphocytic Leukemia, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.
- Burgess M, Gill D, Singhania R, et al. CD62L as a therapeutic target in chronic lymphocytic leukemia. Clin Cancer Res. 2013;19(20):5675–5685.
- Chen YCE, Mapp S, Blumenthal A, et al. The duality of macrophage function in chronic lymphocytic leukaemia. Biochim Biophys Acta Rev Cancer. 2017;1868(1):176–182.
- Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20.
- Enya Chen YC, Burgess M, Mapp S, et al. PI3K-p110delta contributes to antibody responses by macrophages in chronic lymphocytic leukemia. Leukemia. 2020;34(2):451–461.